• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

RCT Results: Does Mifepristone Pretreatment for Termination of Pregnancy After Fetal Loss Improve Time to Delivery?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Allanson et al. (Obstetrics & Gynecology, 2021) assessed the efficacy of pretreatment with mifepristone before misoprostol, compared with misoprostol alone, for termination of pregnancy after a fetal death in the second trimester

METHODS:

  • Prospective, double blind, randomized, placebo-controlled trial
  • Participants
    • Termination for fetal death
    • Between 14 and 28 weeks of gestation
  • Interventions
    • 200 mg mifepristone orally 24 to 48 hours before the termination of pregnancy with misoprostol
      • 14 to 24 weeks: 400 micrograms every 6 hours vaginally
      • 24 to 28 week: 200 micrograms every 4 hours vaginally
    • Placebo before misoprostol
  • Study design
    • A sample size of 116 women per group was planned
    • Trial was ceased after 66 women enrolled secondary to prolonged time to achieve recruitment | Over time of the study, resources were available at other centers and recruitment site was no longer receiving as many patients for this procedure
  • Primary outcome
    • Time from administration of misoprostol to delivery

RESULTS:

  • 34 women received placebo | 32 received mifepristone
    • There were no differences in the characteristics between the groups
  • The median time to delivery was significantly reduced in the mifepristone group
    • Mifepristone + misoprostol: 6.8 hours
    • Placebo + misoprostol: 10.5 hours
    • Hazard ratio 2.41 (95% CI, 1.39 to 4.17); P = 0.002
  • Women in the placebo group also required
    • More doses of misoprostol (P = 0.002)
      • Mifepristone + misoprostol: 2.1 doses
      • Placebo + misoprostol: 3.4 doses
    • More misoprostol overall (P = 0.003)
      • Mifepristone + misoprostol: 767.7 micrograms
      • Placebo + misoprostol: 1,181.8 micrograms
  • There was no difference in maternal complications between the two groups
  • Women in the mifepristone group reported improved perception of the procedure

CONCLUSION:

  • Compared to misoprostol alone, the use of mifepristone prior to misoprostol for termination of pregnancy after fetal death between 14 and 28 weeks significantly reduced the time to delivery and the amount of misoprostol needed
  • The authors conclude

Despite the early termination of our trial, we achieved our planned outcome of a 30% reduction in the median duration of labor

Learn More – Primary Sources:

Pretreatment With Mifepristone Compared With Misoprostol Alone for Delivery After Fetal Death Between 14 and 28 Weeks of Gestation: A Randomized Controlled Trial

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

MifeMiso RCT results: Mifepristone Plus Misoprostol or Misoprostol Alone for Miscarriage Treatment?
Does Adding Mifepristone Prior to Misoprostol Improve Medical Management of Pregnancy Loss?
Triple M RCT Results: Mifepristone Plus Misoprostol for the Management of Early Pregnancy Loss
Is Misoprostol Management Effective for Management of Stillbirth?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site